



First synthesis of naturally occurring ($\pm$)-*epi*-conocarpan

Shi-Long Zheng,^{a,*} Wing-Yiu Yu,^b Ming-Xia Xu^a and Chi-Ming Che^{b,*}


^aWest China School of Pharmacy, Sichuan University, Chengdu 610041, PR China

^bDepartment of Chemistry, The University of Hong Kong, Pokfulam Road, Hong Kong

Received 22 October 2002; revised 5 December 2002; accepted 13 December 2002

Abstract—($\pm$)-*epi*-Conocarpan **1** was synthesized via the key intermediate 5-bromo-*cis*-2-(4-methoxyphenyl)-3-methyl-2,3-dihydrobenzofuran **6** which was synthesized by a ruthenium(II) porphyrin-catalyzed intramolecular C–H insertion reaction using aryl tosylhydrazone salt **5** as the carbene source, starting from the commercially available 5-bromo-2-hydroxyacetophenone. © 2003 Elsevier Science Ltd. All rights reserved.

Piperaceae species are pioneer shrubs with economic and medicinal importance. (–)-*epi*-Conocarpan was isolated from the roots of *Piper regnellii* (Piperaceae).¹ *epi*-Conocarpan **1** is the epimer of conocarpan **2**,² *epi*-conocarpan and *epi*-conocarpan have the 3-methyl-2,3-dihydrobenzofuran skeleton, the basic structure of a sub-class of neolignan natural products which possess a wide variety of antibacterial, cytotoxic, antiproliferative, immunosuppressive, antioxidant, antiangiogenic and insecticidal activities.³ Conocarpan is toxic to the larvae of the European corn borer at 10 $\mu\text{g/mL}$.⁴ However, due to the limited amounts of (–)-*epi*-conocarpan, its biological activity has not yet been established. Here we report the first synthesis of ($\pm$)-*epi*-conocarpan **1**.



Although there are several approaches available for the formation of the 3-methyl-2,3-dihydrobenzofuran skeleton,⁵ all methods yield only the *trans*-3-methyl-2,3-dihydrobenzofurans as the major product. So, the synthesis of the intermediate *cis*-2,3-dihydrobenzofuran derivative **6** is the key step (see Scheme 1). Intra- and intermolecular metal carbene C–H insertion has emerged as a general strategy for the formation of carbocycles and heterocycles.⁶ High-valent oxo- and


imidoruthenium porphyrins are known to effect alkane hydroxylations and amidations via C–H bond activation.⁷ However, our earlier studies revealed that the reaction of $[\text{Ru}^{\text{II}}(\text{TTP})(\text{CO})]$ (H_2TTP = *meso*-tetrakis(*p*-tolyl) porphyrin) with γ -alkoxy- α -diazo- β -ketoesters afforded ruthenium–carbene porphyrin complexes, which then underwent subsequent intramolecular cyclization to furnish 1,3-dioxolanes exclusively.⁸ Fortunately, we recently found the first ruthenium porphyrin-catalyzed intramolecular carbenoid C–H insertion to afford selectively *cis*-2,3-disubstituted-2,3-dihydrobenzofurans using aryl tosylhydrazone salts as the carbene sources.

The reaction conditions of the ruthenium(II) porphyrin-catalyzed intramolecular C–H insertion reactions using aryl tosylhydrazone salt **5** as carbene source to provide 5-bromo-*cis*-2-(4-methoxyphenyl)-3-methyl-2,3-dihydrobenzofuran **6** was investigated. As shown in Table 1, when the $[\text{Ru}^{\text{II}}(\text{TTP})(\text{CO})]$ -catalyzed C–H insertion reaction of **5** was performed in refluxing toluene, the reaction was finished in only 2 h affording **6** in 82% yield, albeit with slightly compromised *cis*-selectivity (entry 3). Phase transfer catalysts (PTC) $n\text{-Bu}_4\text{N}^+\text{Br}^-$ and $\text{BnEt}_3\text{N}^+\text{Cl}^-$ gave similar ratios under identical conditions (entries 1 and 2). Contrary to expectation, $\text{Rh}_2(\text{OAc})_4$ was a less effective catalyst giving low yields and stereoselectivity (entry 5). In the absence of a catalyst, no product was found according to ^1H NMR analysis of the reaction mixture (entry 4).

The benzylation of 5-bromo-2-hydroxyacetophenone with *p*-methoxybenzyl chloride afforded 5-bromo-2-(4-methoxy benzyloxy)acetophenone **3**⁹ under microwave irradiation in only a few minutes, which was then

Keywords: ($\pm$)-*epi*-conocarpan; *cis*-2,3-dihydrobenzofuran; intramolecular C–H insertion; ruthenium(II) porphyrin.

* Corresponding authors. Tel.: 86-28-85501382; fax: 86-28-85437960; e-mail: zshilong1@163.com



Scheme 1. Reagents and conditions: (a) *p*-methoxybenzyl chloride, K_2CO_3 , microwave irradiation, 99%; (b) $TsNHNH_2$, ethanol, reflux, 86%; (c) sodium, methanol; (d) $Bn(Et)_3N^+Cl^-$, $[Ru^{II}(TTP)(CO)]$, toluene, 60–70°C, 48 h, 77% (two steps including c and d); (e) *n*-BuLi, THF, 0.5 h; then DMF, –78–25°C, 1.5 h, 48%; (f) *n*-BuLi, THF, $(Ph)_3P^+EtBr^-$, 79%; (g) $PdCl_2 \cdot 2CH_3CN$, CH_2Cl_2 , 93%; (h) *n*-BuLi, $(Ph)_2PH$, THF, 85%.

Table 1. Ru- or Rh-catalyzed intramolecular C–H insertion reaction to form **6** using aryl tosylhydrazone salt **5** as carbene source

Entry	Catalyst	PTC	Temp. (°C)	Time (h)	Yield (%)	<i>cis:trans</i> ^a
1	$[Ru^{II}(TTP)(CO)]$	<i>n</i> -Bu ₄ N ⁺ Br [–]	60–70	48	77	>98
2	$[Ru^{II}(TTP)(CO)]$	BnEt ₃ N ⁺ Cl [–]	60–70	48	75	>98
3	$[Ru^{II}(TTP)(CO)]$	<i>n</i> -Bu ₄ N ⁺ Br [–]	110 ^b	2	82	84:16
4	None	<i>n</i> -Bu ₄ N ⁺ Br [–]	60–70	48	0	–
5	$[Rh_2(OAc)_4]$	<i>n</i> -Bu ₄ N ⁺ Br [–]	60–70	48	29	76:24

^a The ratio of *cis* to *trans* was determined by ¹H NMR.

^b The reaction was performed in refluxing toluene.

treated with *p*-toluenesulfonylhydrazide to afford 2-(4-methoxybenzyloxy)-5-bromoacetophenone tosylhydrazone **4**⁹ in 86% yield. The compound **4** was transformed to the salt **5** with sodium methoxide, which was formed in situ by the reaction of sodium with methanol. 5-Bromo-*cis*-2-(4-methoxyphenyl)-3-methyl-2,3-dihydrobenzofuran **6**⁹ was formed by $[Ru^{II}(TTP)(CO)]$ -catalyzed intramolecular C–H insertion using the salt **5** as carbene source with high stereoselectivity (>98%, *cis*). The replacement¹⁰ of the bromine substituent in **6** with an aldehyde group using *n*-butyllithium as the metallation reagent and DMF as the formyl source afforded 2-(4-methoxyphenyl)-3-methyl-*cis*-2,3-dihydrobenzofuran-5-carbaldehyde **7**.⁹ The Wittig reaction¹¹ of compound **7** with ethyltriphenylphosphonium bromide using potassium carbonate in moist dioxane led to the formation of an oily mixture of stereoisomers of 2-(4-methoxyphenyl)-3-methyl-5-(1-propenyl)-*cis*-2,3-dihydrobenzofuran. The isomerization reaction^{11b} of the stereo-

isomers using bis-(acetonitrile)dichloropalladium(II) in dichloromethane produced the (*E*)-isomer **8**.⁹ Demethylation^{5b} of **8** with $LiPPh_2$ in anhydrous tetrahydrofuran gave an 85% yield of (±)-*epi*-conocarpan **1** as a crystalline solid with identical spectral data to those of the natural product.¹

In conclusion, a total synthesis of (±)-*epi*-conocarpan was achieved in eight steps with a 20% overall yield from 5-bromo-2-hydroxyacetophenone. Ruthenium(II) porphyrin-catalyzed intramolecular C–H insertion using aryl tosylhydrazone salt **5** as the carbene source provided a general route to the key intermediate 5-bromo-*cis*-2-(4-methoxyphenyl)-3-methyl-2,3-dihydrobenzofuran **6** with high stereoselectivity (>98% *cis*) for the synthesis of **1**. It is our belief that this strategy will be versatile and practical for the synthesis of a variety of other natural products with *cis*-2,3-dihydrobenzofuran skeleton.

References

1. Benevides, P. J. C.; Sartorelli, P.; Kato, M. J. *Phytochemistry* **1999**, *52*, 339–343.
2. (a) Hayashi, T.; Thomson, R. H. *Phytochemistry* **1975**, *14*, 1085–1087; (b) Sartorelli, P.; Benevides, P. J. C.; Ellensohn, R. M.; Rocha, M. V. A. F.; Moreno, P. R. H.; Kato, M. J. *Plant Sci.* **2001**, *161*, 1083–1088.
3. (a) Ward, R. S. *Nat. Prod. Rep.* **1997**, *14*, 43–74; (b) Ward, R. S. *Nat. Prod. Rep.* **1995**, *12*, 183–205; (c) Apers, S.; Paper, D.; Bürgermeister, J.; Baronikova, S.; Van Dyck, S.; Lemièrre, G.; Vlietinck, A.; Pieters, L. *J. Nat. Prod.* **2002**, *65*, 718–720; (d) Chen, C.-H.; Shaw, C.-Y.; Chen, C.-C.; Tsai, Y.-C. *J. Nat. Prod.* **2002**, *65*, 740–741; (e) Tsai, I.-L.; Hsien, C.-F.; Duh, C.-Y. *Phytochemistry* **1998**, *48*, 1371–1375; (f) Gordaliza, M.; Castro, M.; Corral, J. M.; Lopez-Vazquez, M.; Feliciano, A. S.; Faircloth, G. T. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 2781–2786.
4. Chauret, D. C.; Bernand, C. B.; Arnason, J. T.; Durst, T.; Krishnamurthy, H.; Sanchez-Vindas, P.; Moreno, N.; Roman, L. S.; Poveda, L. *J. Nat. Prod.* **1996**, *59*, 152–155.
5. (a) Engler, T. A.; Letavic, M. A.; Iyengar, R.; La Tessa, K. O.; Reddy, J. P. *J. Org. Chem.* **1999**, *64*, 2391–2405; (b) Snider, B. B.; Han, L.; Xie, C. *J. Org. Chem.* **1997**, *62*, 6978–6984; (c) Chiba, K.; Fukuda, M.; Kim, S.; Kitano, Y.; Tada, M. *J. Org. Chem.* **1999**, *64*, 7654–7656; (d) Horne, D. A.; Yakushijin, K.; Büchi, G. *Tetrahedron Lett.* **1999**, *40*, 5443–5447.
6. (a) Sulikowski, G. A.; Cha, K. L.; Sulikowski, M. M. *Tetrahedron: Asymmetry* **1998**, *9*, 3145–3169; (b) Davies, H. M. L.; Antoulinakis, E. G. *J. Organomet. Chem.* **2000**, *617–618*, 47–55.
7. (a) Che, C.-M.; Yu, W.-Y. *Pure Appl. Chem.* **1999**, *71*, 281–288; (b) Au, S.-M.; Huang, J.-S.; Yu, W.-Y.; Fung, W.-H.; Che, C.-M. *J. Am. Chem. Soc.* **1999**, *121*, 9120–9132.
8. Zheng, S.-L.; Yu, W.-Y.; Che, C.-M. *Org. Lett.* **2002**, *4*, 889–892.
9. Selected spectroscopic and physicochemical properties: compound **3**, colorless crystal, ^1H NMR (400 MHz, CDCl_3): δ 7.84 (d, $J=2.6$ Hz, 1H); 7.52 (dd, $J=2.6$ Hz and 8.8 Hz, 1H); 7.35 (d, $J=8.7$ Hz, 2H); 6.92 (m, 3H); 5.07 (s, 2H); 3.83 (s, 3H); 2.55 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 198.3, 159.7, 157.1, 136.0, 133.0, 130.1, 129.4, 127.7, 114.8, 114.1, 113.3, 70.8, 55.3, 32.0. IR (KBr, cm^{-1}): 2928, 1666, 1616, 1586, 1515, 1483, 1459, 1280, 1239, 1034, 643, 523. MS (EI): 334 (M^+ , 2), 258 (22), 228 (25), 197 (20), 150 (15), 135 (17), 121 (100), 107 (15). HRMS (EI): Found M^+ 334.0211, $\text{C}_{16}\text{H}_{15}\text{BrO}_3$ requires 334.0205. Anal. calcd for $\text{C}_{16}\text{H}_{15}\text{BrO}_3$: C, 57.33; H, 4.51. Found: C, 57.44; H, 4.50%. Compound **4**, colorless crystal, ^1H NMR (400 MHz, CDCl_3): δ 7.88 (d, $J=8.3$ Hz, 2H); 7.53 (bs, 1H); 7.38–7.22 (m, 6H); 6.90–6.78 (m, 3H); 4.93 (s, 2H); 3.82 (s, 3H); 2.44 (s, 3H); 2.04 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 159.6, 155.7, 144.2, 135.3, 132.9, 132.6, 130.2, 129.6, 129.1, 128.2, 128.0, 114.2, 114.0, 113.1, 70.6, 55.5, 21.7, 16.7. IR (KBr, cm^{-1}): 3203, 2934, 1612, 1587, 1514, 1486, 1463, 1397, 1375, 1337, 1299, 1235, 1046, 990, 915, 817, 660, 592. MS (EI): 502 (M^+ , 0.6), 318 (9), 224 (3), 139 (3), 121 (100), 108 (4). HRMS (EI): Found M^+ 502.0562, $\text{C}_{23}\text{H}_{23}\text{BrN}_2\text{O}_4\text{S}$ requires 502.0562. Compound **6**, colorless oil, ^1H NMR (400 MHz, CDCl_3): δ 7.28–7.17 (m, 4H); 6.90–6.86 (m, 2H); 6.76 (d, $J=8.1$ Hz, 1H), 5.77 (d, $J=8.8$ Hz, 1H); 3.81 (s, 3H); 3.64 (m, 1H); 0.81 (d, $J=7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 159.2, 158.3, 135.3, 130.9, 129.5, 127.5, 127.4, 113.6, 112.4, 111.0, 88.2, 55.2, 40.9, 16.7. IR (neat, cm^{-1}): 2964, 2929, 1613, 1586, 1513, 1470, 1304, 1250, 1172, 1034, 957, 809, 657. MS (EI): 320 (89), 318 (M^+ , 100), 224 (19), 134 (12), 121 (36), 108 (5). HRMS (EI): Found M^+ 318.0256, $\text{C}_{16}\text{H}_{15}\text{BrO}_2$ requires 318.0255. Anal. calcd for $\text{C}_{16}\text{H}_{15}\text{BrO}_2$: C, 60.21; H, 4.74. Found: C, 59.98; H, 4.67%. Compound **7**, colorless liquid, ^1H NMR (400 MHz, CDCl_3): δ 9.86 (s, 1H), 7.74–7.72 (m, 2H), 7.20–7.16 (m, 2H), 6.99 (m, 1H), 6.91–6.89 (m, 2H), 5.90 (d, $J=9.0$ Hz, 1H), 3.81 (s, 3H), 3.75 (m, 1H), 0.88 (d, $J=8.3$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 190.6 (d), 164.8 (s), 159.4 (s), 134.3 (s), 133.3 (d), 130.9 (s), 129.0 (s), 127.5 (d), 125.4 (d), 113.8 (d), 109.7 (d), 89.2 (d), 55.3 (q), 40.0 (d), 16.7 (q). IR (neat, cm^{-1}): 3354, 2969, 2928, 2836, 1744, 2252, 1684, 1604, 1514, 1332, 1243, 1175, 1090, 1033, 949, 823, 728, 627. MS (EI): 269 (M^+ , 21), 268 (M^+ , 100), 266 (19), 253 (11), 121 (13). HRMS (EI): Found M^+ 268.1101, $\text{C}_{17}\text{H}_{16}\text{O}_3$ requires 268.1099. Compound **8**, colorless liquid, ^1H NMR (400 MHz, CDCl_3): δ 7.22–7.11 (m, 4H); 6.91–6.86 (m, 2H); 6.80 (d, $J=8.2$ Hz, 1H); 6.36 (dd, $J=15.7$ Hz and 1.5 Hz, 1H); 6.07 (m, 1H); 5.75 (d, $J=8.7$ Hz, 1H); 3.80 (s, 3H); 3.62 (m, 1H); 1.86 (dd, $J=6.6$ Hz and 1.6 Hz, 3H); 0.82 (d, $J=7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 159.1, 158.3, 133.1, 131.3, 130.8, 130.1, 127.6, 126.2, 122.9, 121.5, 113.6, 109.2, 87.9, 55.3, 40.8, 18.4, 16.8. IR (neat, cm^{-1}): 3020, 2963, 2929, 1614, 1515, 1488, 1243, 961, 823. MS (EI): 281 (M^+ , 18), 280 (M^+ , 100), 279 (7), 278 (31), 265 (11), 263 (5), 121 (5). HRMS (EI): Found M^+ 280.1467, $\text{C}_{19}\text{H}_{20}\text{O}_2$ requires 280.1463. Anal. calcd for $\text{C}_{19}\text{H}_{20}\text{O}_2$: C, 81.40; H, 7.19. Found: C, 81.23; H, 7.18%.
10. (a) Dalla, V.; Cotellet, P. *Tetrahedron* **1999**, *55*, 6923–6930; (b) Kende, A. S.; Zhong, M. *Synth. Commun.* **1999**, *29*, 3401–3407.
11. (a) Matikainen, J. K.; Kaltia, S.; Hase, T. *Synlett* **1994**, 817–818; (b) Giles, R. G. F.; Lee Son, V. R.; Sargent, M. V. *Aust. J. Chem.* **1990**, *43*, 777–781.